الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
A series of novel 2-(arylidenehydrazono)-5-(2-oxo-2-arylethyl)thiazolidin-4-ones were synthesized and evaluated for their in vitro cytotoxicity. Among the series, compounds 3, 6, 10, 16, 17 and 24 showed remarkable anticancer activity with mean IC50 values 2.34, 0.73, 2.69, 3.40, 1.18 and 1.76 μg/ml respectively, against MCF-7 cancer cells. Compound 16 enhanced the concentration of caspase-9, inhibited the concentration of KI67, showed a profound reduction in the amount of MMP9 and down-regulation the concentration of VEGF secreted into the medium of MCF-7 treated cells. Molecular docking was performed for the most effective anticancer compounds to rationalize the possible interactions within VEGFR-2 active site.